Stock Market Reviews

Read and share opinions on PTHS (Pelthos Therapeutics Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock marke

Latest News

• Pelthos Therapeutics Expands Board of Directors with the Appointment of Andrew Einhorn
  Dec 23, 2025
• Pelthos Therapeutics Signs Major Pharmacy Benefit Manager Agreement Expanding Patient Access to ZELSUVMI™ (berdazimer) Topical Gel, 10.3%
  Dec 4, 2025
• Pelthos Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference
  Dec 2, 2025
• Pelthos Therapeutics Announces Third Quarter Fiscal 2025 Financial Results
  Nov 13, 2025
• Pelthos Therapeutics to Report Third Quarter 2025 Financial Results on November 13, 2025
  Nov 5, 2025
• Pelthos Therapeutics Launches Moms Against Molluscum Movement to Unite Families Affected by Molluscum Contagiosum
  Oct 9, 2025
• Pelthos Therapeutics to Participate in Upcoming September Investor Conferences
  Sep 8, 2025
• Pelthos Therapeutics to Participate in the 2025 Wells Fargo Healthcare Conference
  Sep 2, 2025
• Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics
  Jul 2, 2025
• Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement
  Jul 2, 2025

PTHS News

• Pelthos Therapeutics Expands Board of Directors with the Appointment of Andrew Einhorn
  Seasoned executive brings four decades of finance, capital markets, and life sciences experienceDURHAM, N.C., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announced it has named veteran finance executive Andrew J. Einhorn to its Board of Directors effective immediately. Mr. Einhorn will serve on the Board of Directors until Pelt
  Dec 23, 2025
• Pelthos Therapeutics Signs Major Pharmacy Benefit Manager Agreement Expanding Patient Access to ZELSUVMI™ (berdazimer) Topical Gel, 10.3%
  ZELSUVMI is the first and only FDA-approved at-home treatment for molluscum contagiosum, a highly contagious viral skin condition affecting an estimated 16.7 million people, with up to 6 million new incidents reported every year in the United States DURHAM, N.C., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announced it has sign
  Dec 4, 2025
• Pelthos Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference
  DURHAM, N.C., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announced that Pelthos’ CEO Scott Plesha will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference (the “Conference”) on December 4, 2025 at 9:30 a.m. Eastern Time at The Lotte New York Palace located at 455 Madison Avenue, New York, NY 1
  Dec 2, 2025
• Pelthos Therapeutics Announces Third Quarter Fiscal 2025 Financial Results
  Conference call scheduled for November 13, 2025 at 8:00am ET Commercial launch of ZELSUVMI, the first FDA-approved at-home molluscum contagiosum treatment, exceeded expectations and generated $7.1 million in net revenues 2,716 ZELSUVMI units prescribed by 1,169 unique prescribers in the third quarter of fiscal 2025 DURHAM, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic produc
  Nov 13, 2025
• LGND: Target Up On Improved Growth Outlook
  By John Vandermosten, CFA NASDAQ:LGND READ THE FULL LGND RESEARCH REPORT Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) reported outstanding results for its third quarter, with revenues almost double our estimates and adjusted core earnings per share (EPS) more than 60% greater. While contributions from the spin out of Pelthos contributed the most, revenue growth in other areas was also strong.
  Nov 10, 2025
• Pelthos Therapeutics Acquires Xepi® (ozenoxacin) Cream, 1% and Announces $18 Million Private Convertible Notes Financing
  Acquisition adds complementary dermatology product to the Pelthos portfolio anchored by ZELSUVMI™Xepi is a novel FDA-approved topical treatment for impetigo that addresses a critical unmet need in antibiotic-resistant skin infections caused by staph and strep infections, most commonly affecting childrenImpetigo affects approximately 3 million people in the U.S. every year and is among the most common bacterial skin infections seen in pediatric officesPrivate convertible notes financing will supp
  Nov 7, 2025
• Pelthos Therapeutics to Report Third Quarter 2025 Financial Results on November 13, 2025
  Company to hold a conference call at 8:00 a.m. ETDURHAM, N.C., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), will hold a conference call on Thursday, November 13, 2025, at 8:00 a.m. Eastern Time to discuss its results for the third quarter period ended September 30, 2025. The financial results will be issued in a press release prior to
  Nov 5, 2025
• Pelthos Therapeutics Launches Moms Against Molluscum Movement to Unite Families Affected by Molluscum Contagiosum
  The Moms Against Molluscum movement aims to empower families impacted by molluscum to share their personal stories and encourage others to join the conversationMolluscum is a highly contagious skin infection affecting 16.7 million Americans, mainly childrenMomsAgainstMolluscum.com will offer new resources to support moms, parents, and other caregivers of molluscum patients DURHAM, N.C., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company
  Oct 9, 2025
• Presenting at the Investor Summit Q3 2025 on September 16; Watch the Live Stream for Free
  NEW YORK, NY / ACCESS Newswire / September 16, 2025 /Investor Summit Group, the premier destination for virtual microcap conferences, is proud to announce the schedule for its upcoming Q3 Investor Summit Virtual on Sept 16, 2025. Designed to maximize ...
  Sep 16, 2025
• Pelthos Therapeutics to Participate in Upcoming September Investor Conferences
  DURHAM, N.C., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company (“Pelthos” or the “Company”) committed to commercializing innovative therapeutic products for high unmet patient needs, today announced that Scott Plesha, CEO, and Frank Knuettel II, CFO, will participate in the upcoming September conferences: H.C. Wainwright 27th Annual Global Investment Conference and the Investor Summit Group Q3 Virtual Conference. Investor Conference
  Sep 8, 2025
• Pelthos Therapeutics to Participate in the 2025 Wells Fargo Healthcare Conference
  Management’s presentation will take place on Wednesday, September 3rd, 2025 at 1:30 pm (ET)DURHAM, N.C., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company (“Pelthos” or the “Company”) committed to commercializing innovative therapeutic products for high unmet patient needs, today announced that Scott Plesha, CEO, and Frank Knuettel, CFO, will participate in the Wells Fargo Healthcare Conference. Management’s presentation will take pla
  Sep 2, 2025
• Pelthos Therapeutics Reports Second Quarter 2025 Financial Results for Legacy Operations and Provides Business Update
  Files Quarterly Report on Form 10-Q detailing financial results for legacy operations for the three and six months ended June 30, 2025Strong physician response following successful launch of ZELSUVMI™ (berdazimer) topical gel 10.3%, the first and only FDA-approved at-home treatment for molluscum contagiosum for patients one year of age and olderCompletes build-out of essential management operational infrastructure and hires 50 territory sales managers DURHAM, N.C., Aug. 18, 2025 (GLOBE NEWSWIRE)
  Aug 18, 2025
• Sector Update: Health Care Stocks Rise Late Afternoon
  Health care stocks advanced late Thursday afternoon, with the NYSE Health Care Index rising 0.9% and
  Jul 10, 2025
• Pelthos Therapeutics Launches ZELSUVMI™ (berdazimer) Topical Gel 10.3%, the First and Only FDA-Approved At-Home Treatment for Molluscum Contagiosum
  ZELSUVMI is now commercially available via prescription through retail pharmacies, ASPN pharmacy services and for at-home delivery through mail-order pharmaciesOnce-daily topical prescription medication can be applied by patients, parents and caregivers outside of a physician's office, at home or on the goMolluscum contagiosum is a highly contagious viral skin condition that afflicts an estimated 16.7 million people with up to 6 million new incidents per year in the United States, most of them c
  Jul 10, 2025
• Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement
  The combined company plans to launch ZELSUVMI™ for the treatment of molluscum contagiosum infections in July 2025 Concurrent with the closing of the merger, the combined company closed on a $50.1 million equity private placement Combined company will operate under the name “Pelthos Therapeutics Inc.” and will trade on the NYSE American exchange under the ticker symbol “PTHS” starting on July 2, 2025 DURHAM, N.C., July 02, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc., a biopharmaceutical co
  Jul 2, 2025
• Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics
  Pelthos plans to launch ZELSUVMI™ for the treatment of Molluscum contagiosum infections in July 2025 Concurrent with the closing of the merger, Ligand has invested $18 million in the combined company and is entitled to a 13% royalty on worldwide sales of ZELSUVMI Pelthos will commence trading on the NYSE American exchange under the new ticker symbol “PTHS” on July 2, 2025 JUPITER, Fla., July 02, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced the compl
  Jul 2, 2025

PTHS Reviews

• CapitalRush

  Dec 29, 2025

  $PTHS By pioneering groundbreaking therapies, this biotech firm is at the forefront of addressing unmet medical needs. Its strong pipeline and strategic collaborations show promise for significant advancements in treatment options.

  Buy

• CodeAndCapital

  Dec 29, 2025

  $PTHS Sounds like a name for a superhero team saving us from boring pharmaceuticals—let’s hope they have cool costumes!

  Buy

• BuyTheDipBro

  Dec 29, 2025

  $PTHS Therapeutics are the future, watch this one for new kicks!

  Buy

• BearMarketSurvivor

  Dec 28, 2025

  $PTHS This joint is cooking up some wild potential, keep an eye on 'em!

  Buy

• StockShotz

  Dec 28, 2025

  $PTHS This stock's like a tutorial video that promises to teach you everything—only to leave you confused and wondering where you went wrong!

  Sell

• AlphaRogue

  Dec 26, 2025

  $PTHS This stock is like a superhero in a lab coat – fighting diseases and saving the day, one breakthrough at a time! Talk about a cape-worthy mission!

  Buy

• WallStreetBandit

  Dec 25, 2025

  $PTHS A biotech that’s more about hype than healing.

  Sell

• TradePredator

  Dec 25, 2025

  $PTHS Therapeutics? More like therapeutic boredom.

  Sell

• BuyLowBoi

  Dec 24, 2025

  $PTHS In the shadows, but could shine bright if things align.

  Sell

• BuyLowBoi

  Dec 24, 2025

  $PTHS They're mixin' tough science and ambitions, watch this one closely.

  Buy

• FiscalRogue

  Dec 24, 2025

  $PTHS Therapeutics or not, this one feels like a placebo.

  Sell

• TheEarningsBeast

  Dec 24, 2025

  $PTHS This stock is like your favorite video game—promising epic levels but you might end up just watching the cutscenes!

  Sell

• ChartPhantom

  Dec 24, 2025

  $PTHS If this stock were a science project, it’d definitely be the one with the exploding volcano—exciting, but maybe best from a distance!

  Sell

• FiscalFrost

  Dec 24, 2025

  $PTHS Emphasizing novel therapeutic approaches, this company is making strides in addressing unmet medical needs. Its dedication to research and development is notable and could lead to revolutionary treatments in the healthcare sector.

  Buy

• BearishBoi

  Dec 23, 2025

  $PTHS They’re in the therapeutic game, but is it really a cure or just a band-aid on a budget?

  Sell

• OptionShadow

  Dec 23, 2025

  $PTHS In a rapidly evolving healthcare landscape, this company is at the cutting edge of therapeutic developments. Their research-driven approach indicates a robust pipeline that could yield significant breakthroughs.

  Buy

• MarginLogic

  Dec 22, 2025

  $PTHS This biotech firm is at the forefront of developing groundbreaking therapies. Their research-focused strategy could lead to significant advancements in treatment options, appealing to a growing patient base.

  Buy

• DividendDemon

  Dec 21, 2025

  $PTHS Getting involved here feels like trying to navigate a maze—you might end up surprised or totally lost!

  Sell

• CashCraze

  Dec 21, 2025

  $PTHS In the biotech space, this firm is dedicated to developing groundbreaking therapies that address significant unmet medical needs. Its ongoing research initiatives could yield promising results, making it a noteworthy player in the industry.

  Buy

• TheLongPlay

  Dec 20, 2025

  $PTHS Therapeutics on deck, watch it bloom like spring flowers!

  Buy

• LazyQuant

  Dec 20, 2025

  $PTHS Pelthos sounds like a potion from a fantasy novel, but this one might actually brew up some profits instead of magic spells!

  Buy

• ShortCircuit

  Dec 19, 2025

  $PTHS Therapeutics? More like 'thera-pit-ics'—this stock's a total flop.

  Sell

• RiskAssassin

  Dec 19, 2025

  $PTHS In the chaotic world of therapeutics, this newcomer faces daunting hurdles. Will they make the breakthrough needed or crash and burn in the pressure cooker of innovation?

  Sell

• EquityAssault

  Dec 19, 2025

  $PTHS Yet another overhyped biotech with nothing substantial to show.

  Sell

• TendieTitan

  Dec 19, 2025

  $PTHS Pushing boundaries in healthcare like your mom pushes you to clean your room!

  Buy

• DividendDemon

  Dec 18, 2025

  $PTHS This stock is like a secret recipe – a bit mysterious but could be the key ingredient to a great portfolio!

  Buy

• ShortSurge

  Dec 18, 2025

  $PTHS The company is on a path to revolutionize therapeutic approaches through its unique methodologies. As advancements in treatment options grow, its focus on patient-centric solutions may yield favorable outcomes.

  Buy

• TradingNomad

  Dec 17, 2025

  $PTHS In the unpredictable world of therapeutics, one breakthrough can change everything. The tension mounts as the market watches closely; will they rise to the occasion or fall short?

  Sell

• CapitalCrusher

  Dec 17, 2025

  $PTHS This firm is like that weird science project that turns out to be brilliant. Who knew mixing things up could create magic?

  Buy

• BearBreaker

  Dec 16, 2025

  $PTHS Hope this doesn't end up in the graveyard of failed biotech.

  Sell

• TickerTyrant

  Dec 16, 2025

  $PTHS Promises more than it delivers—shocking, right?

  Sell

• BullishMyth

  Dec 16, 2025

  $PTHS This company is on the cutting edge of therapeutic innovation, but the competition is fierce and unpredictable. Investors need to weigh the potential against the risks of breakthrough failures. It's a nail-biter!

  Buy

• BullishMyth

  Dec 15, 2025

  $PTHS With the biotech sector facing relentless scrutiny, this stock's future hinges on the next big announcement. Nervous investors are holding their breath—what’s next?

  Buy

• ShortKingston

  Dec 15, 2025

  $PTHS Investing here feels like hitting the jackpot at a bingo night—unexpected and filled with hope!

  Buy

• MarginMythic

  Dec 14, 2025

  $PTHS Breakout potential is m$!!ive.

  Buy

• CandleBinary

  Dec 14, 2025

  $PTHS This company appears to be in a strong position with its groundbreaking research initiatives, potentially leading to significant advancements in its field.

  Buy

• TickerTakedown

  Dec 14, 2025

  $PTHS Imagine a lab full of mad scientists cooking up the next big thing in healthcare. You’re gonna want an invite to this party!

  Buy

• StonkKnight

  Dec 13, 2025

  $PTHS New on the block, but could blow up big time, keep an eye!

  Buy

• ShortCircuit

  Dec 13, 2025

  $PTHS A pipeline of hope that leads into a black hole of despair.

  Sell

• BullRaid

  Dec 13, 2025

  $PTHS Short sellers pressing advantage.

  Sell

• TradeMatrix

  Dec 12, 2025

  $PTHS In the world of therapeutics, every breakthrough feels like a ticking time bomb. Can this company handle the pressure, or will they implode under expectations?

  Buy

• TradeMatrix

  Dec 12, 2025

  $PTHS The biotech sector is buzzing, and this company is in the thick of it. With breakthroughs around the corner, the pressure is mounting—failure could lead to a dizzying drop, while success might skyrocket their future.

  Buy

• BullishVanguard

  Dec 12, 2025

  $PTHS A therapy that sounds better than it performs.

  Sell

• CapitalHex

  Dec 12, 2025

  $PTHS Market leaning heavily bullish here.

  Buy

• GainVector

  Dec 12, 2025

  $PTHS Macro headwinds increasing risk.

  Sell

• RiskDriver

  Dec 12, 2025

  $PTHS Bearish shockwave forming.

  Sell

• MarketSavage

  Dec 12, 2025

  $PTHS Therapeutics? They need some for their declining stock.

  Sell

• TradeGoblin

  Dec 11, 2025

  $PTHS This joint's got mad potential in the biotech game, keep an eye on it!

  Buy

• BullishBard

  Dec 11, 2025

  $PTHS Here’s a company with more potential than my New Year’s resolutions—just waiting to be unleashed!

  Buy

• FiscalRogue

  Dec 11, 2025

  $PTHS Weak chart with clear sell signals.

  Sell

• DividendGhost

  Dec 11, 2025

  $PTHS Market sentiment shifting positive.

  Buy

• HedgeKnight

  Dec 10, 2025

  $PTHS They’re working on the science of turning frowns into smiles—just don’t mix them up with your chemistry homework!

  Buy

• CapitalFrame

  Dec 10, 2025

  $PTHS Emerging as an innovator in the biotechnology sector, this firm is dedicated to pioneering therapeutic solutions that address unmet medical needs, presenting a compelling opportunity for investors interested in future-focused healthcare advancements.

  Buy

• VolatileViking

  Dec 9, 2025

  $PTHS Think of this stock as the underdog superhero in a movie—full of potential and ready to save the day with some serious breakthroughs.

  Buy

• AlphaRift

  Dec 9, 2025

  $PTHS Operating in a niche sector of biotech, this firm is dedicated to advancing medical research that could lead to vital new treatments. Their innovative pipeline reflects a commitment to addressing complex health challenges.

  Buy

• QuantAssault

  Dec 9, 2025

  $PTHS Price action tight and bullish.

  Buy

• YieldWarden

  Dec 9, 2025

  $PTHS Big rejection wick at highs.

  Sell

• BuyLowBro

  Dec 8, 2025

  $PTHS Doing superhero work in therapeutics! Move over, Marvel, there’s a new hero in town.

  Buy

• AlphaDruid

  Dec 8, 2025

  $PTHS In the high-stakes world of therapeutics, this company's innovative approach could be a game changer or a costly misstep. The risk is high, and the stakes are even higher!

  Sell

• ShortRaid

  Dec 7, 2025

  $PTHS With a focus on groundbreaking therapeutic developments, this organization is venturing into an area of high unmet medical needs. Its innovative approach could pave the way for significant advancements in treatment options.

  Buy

• TradeBlitz

  Dec 6, 2025

  $PTHS This one’s got the potential to be the superhero we didn’t know we needed! Cape not included.

  Buy

• BuyLowBro

  Dec 6, 2025

  $PTHS This biotech might be cooking up some serious magic in the lab. Just don't expect their potions to come with a side of fries!

  Buy

• BullBrawler

  Dec 6, 2025

  $PTHS Bulls pushing relentlessly.

  Buy

• ProfitVortex

  Dec 6, 2025

  $PTHS This stock is like a secret recipe for success—just sprinkle a little hope and watch the magic unfold!

  Buy

• TradeHex

  Dec 5, 2025

  $PTHS This biotech firm is exploring groundbreaking therapies that could address unmet medical needs, reflecting its innovative approach to healthcare.

  Buy

• BullishBerserker

  Dec 5, 2025

  $PTHS This one’s in a niche market and is struggling for traction. While the science sounds promising, the pressure to perform is intense, and doubts are creeping in.

  Sell

• CodeTrader

  Dec 5, 2025

  $PTHS In the dynamic world of therapeutics, breakthroughs can mean everything. Pressure mounts to deliver results as investors watch closely for signs of promise or failure. It's a nail-biter!

  Buy

• CashWraith

  Dec 4, 2025

  $PTHS This company is pushing the envelope in therapeutics, and the excitement is palpable, but the pressure to deliver results is through the roof! Will they meet expectations or crumble under the weight?

  Buy

• BullishShade

  Dec 4, 2025

  $PTHS Troubling weakness everywhere.

  Sell

• TendieTitan

  Dec 4, 2025

  $PTHS Support breaking — bearish continuation.

  Sell

• MarginMyth

  Dec 4, 2025

  $PTHS Bearish structure forming clearly.

  Sell

• PnLReaper

  Dec 4, 2025

  $PTHS Bearish structure strengthening.

  Sell

• DiamondHands

  Dec 3, 2025

  $PTHS This stock has the vibe of a superhero origin story - it’s got potential but might just need a little more time to save the day!

  Buy

• PortfolioFreak

  Dec 3, 2025

  $PTHS With their ambitious goals in therapeutics, the spotlight is on. Can they deliver breakthroughs or risk becoming another name lost in the shuffle? Every day feels like a boiling pot about to overflow!

  Buy

• PaperHandsGone

  Dec 2, 2025

  $PTHS This one's in the lab, brewing up something special, watch it explode!

  Buy

• EquityAssault

  Dec 2, 2025

  $PTHS The only thing this company is good at is underwhelming everyone.

  Sell

• BullishVanguard

  Dec 2, 2025

  $PTHS Betting on this is like putting money on a losing horse—painful.

  Sell

• AlphaRift

  Dec 2, 2025

  $PTHS As a therapeutic company, they are pioneering advancements in treatment options, which may address significant unmet medical needs. Their innovative research initiatives could position them favorably within the healthcare sector.

  Buy

• WallStreetGrim

  Dec 2, 2025

  $PTHS This innovative company is at the forefront of developing groundbreaking therapies. Their focus on addressing unmet medical needs showcases a commitment to improving patient outcomes and advancing the biopharmaceutical landscape.

  Buy

• StonkPhantom

  Dec 1, 2025

  $PTHS Navigating the therapeutic space feels like walking a tightrope. Breakthroughs are anticipated, but the uncertainty looms large. Can they stay ahead in this race against time and market dynamics?

  Buy

• QuantSpecter

  Dec 1, 2025

  $PTHS In the biotech world, the anticipation is almost unbearable! Breakthroughs can lead to unimaginable highs, but setbacks could spell disaster. The anxiety surrounding their next steps is real!

  Buy

• ShortCircuit

  Dec 1, 2025

  $PTHS This company sounds like a science fair project gone wrong.

  Sell

• YieldMyth

  Dec 1, 2025

  $PTHS Playing the long game, this crew's got some serious potential.

  Buy

• ShortKingston

  Nov 29, 2025

  $PTHS Therapeutics? I need some therapy for all my bad puns! Maybe they can help with that too!

  Buy

• MarketSavage

  Nov 29, 2025

  $PTHS If only their pipeline was as promising as their buzz.

  Sell

• TradePhantom

  Nov 29, 2025

  $PTHS Therapeutics? More like a therapeutic waste of time.

  Sell

• BullBrawler

  Nov 29, 2025

  $PTHS Therapeutics? More like a therapeutic letdown for investors.

  Sell

• MarketWolf

  Nov 29, 2025

  $PTHS Researching biotech feels like walking a tightrope. There’s enormous potential, but one misstep and everything can come crashing down! It's exciting yet terrifying, and the stakes are incredibly high!

  Sell

• CodeTrader

  Nov 27, 2025

  $PTHS The excitement surrounding this therapeutics company is heart-stopping! Just when you think it’s on the verge of a breakthrough, uncertainty looms large.

  Buy

• MoneyMage

  Nov 26, 2025

  $PTHS With results like these, who needs failure?

  Sell

• PnLPhantom

  Nov 26, 2025

  $PTHS This one's got the potential to be a game-changer, but will it deliver amidst the fierce competition? Tension is high as investors anxiously await any signs of life!

  Buy

• VolatileViking

  Nov 25, 2025

  $PTHS Sounds like a company that helps you feel better about Monday mornings. Who wouldn’t want that?

  Buy

• WallStreetWolf

  Nov 24, 2025

  $PTHS Working on therapeutics like a chef perfecting a secret sauce—let's hope it’s finger-lickin' good!

  Buy

• ShortKingston

  Nov 24, 2025

  $PTHS With a name like that, you can expect some fancy footwork in the market—just try not to trip over the competition!

  Buy

• MoneyMage

  Nov 22, 2025

  $PTHS Therapeutics? More like therapeutic for your losses.

  Sell

• StonkSamurai

  Nov 22, 2025

  $PTHS This joint's got potential, making moves like a boss!

  Buy

• MarginMyth

  Nov 21, 2025

  $PTHS A pharmaceutical path with plenty of potholes ahead.

  Sell

• CandleBinary

  Nov 20, 2025

  $PTHS With a focus on pioneering treatments for unmet medical needs, this company is poised to make significant strides in the pharmaceutical industry. Its innovative approach and commitment to research could lead to groundbreaking developments.

  Buy

• LiquidityLord

  Nov 20, 2025

  $PTHS This biotechnology firm is working on novel therapeutics that hold great potential for treating challenging conditions. Their dedication to research and innovative approaches could attract significant interest in the healthcare community.

  Buy

• ShortSavage

  Nov 20, 2025

  $PTHS With the race to bring new therapeutics to market heating up, this firm is in a high-pressure zone. Every trial outcome could swing fortunes dramatically—what’s the next move?

  Buy

• ProfitLancer

  Nov 20, 2025

  $PTHS Therapeutics are great... if only they had a clue.

  Sell

• TheFiscalShade

  Nov 19, 2025

  $PTHS Treading softly but could surprise like a sneak attack!

  Sell

• BullBrawler

  Nov 19, 2025

  $PTHS This one's a long shot, and not in a fun way.

  Sell

• EquityEnigma

  Nov 19, 2025

  $PTHS Therapeutics hold promise, but is this company up to the challenge? The competition is ruthless, and any mistake could mean disaster. Everyone is on high alert, waiting for that critical update!

  Sell

• GainMachine

  Nov 19, 2025

  $PTHS Think of this stock as the quiet genius in class—always there, working on something super important, but nobody really knows until they ace the final!

  Buy

• QuantSpecter

  Nov 18, 2025

  $PTHS Emerging in the biotech scene can feel like walking a tightrope. Every breakthrough is a potential game-changer, but the stakes have never been higher!

  Buy

• TheChartCode

  Nov 18, 2025

  $PTHS These guys are the Sherlock Holmes of therapeutics—solving problems like a champ! 🔍💊

  Buy

• LiquidKnight

  Nov 18, 2025

  $PTHS Emerging with innovative solutions, this entity is stirring excitement. But, can it stand the fierce scrutiny that comes with high expectations? What a tense waiting game!

  Buy

• StockNova

  Nov 18, 2025

  $PTHS As a player in the biopharmaceutical space, this company is on the cutting edge of developing therapies that address critical health needs. Their pipeline, focused on transformative treatments, has the potential to make significant impacts in patient care.

  Buy

• CandleBinary

  Nov 17, 2025

  $PTHS With a commitment to advancing therapeutic solutions, this organization is at the forefront of addressing significant medical challenges. Its innovative pipeline and dedication to research suggest potential for transformative impacts in the healthcare sector.

  Buy

• FiscalFury

  Nov 17, 2025

  $PTHS This stock feels like that hidden gem in a thrift store—might take some digging, but it’s definitely worth it!

  Buy

• MarketSavage

  Nov 17, 2025

  $PTHS Therapeutics? More like a therapeutic nap after hearing about them.

  Sell

• CapitalFrame

  Nov 17, 2025

  $PTHS With a focus on groundbreaking therapeutic solutions, this firm is at the forefront of addressing critical health challenges. Their robust pipeline and strategic partnerships provide a solid foundation for continued advancement in the biotech sector.

  Buy

• StonkSlayer

  Nov 16, 2025

  $PTHS This stock is like the mysterious kid in class—everyone’s curious about what they’re up to, and it could be something epic!

  Buy

• TheFiscalShade

  Nov 16, 2025

  $PTHS Cookin' up some crazy potential, keep your eyes peeled!

  Buy

• BuyLowBro

  Nov 15, 2025

  $PTHS This one is like a lab experiment gone right—lots of potential, but you might get your hair frizzed out in the process!

  Buy

• TrendHunter

  Nov 15, 2025

  $PTHS Another biotech hoping for a miracle; good luck with that.

  Sell

• OptionCipher

  Nov 15, 2025

  $PTHS What a wild card! If you can handle the ups and downs, this one could explode. But watch out for hidden pitfalls lurking around every corner!

  Sell

• FinTechFrost

  Nov 15, 2025

  $PTHS This stock is like the mad scientist of the market—always cooking up something wild and unexpected. Who knows what genius will come next?

  Buy

• PortfolioFreak

  Nov 15, 2025

  $PTHS In the biotech realm, the race against time is intense! Breakthroughs can change everything, but every moment lost feels like a ticking clock counting down.

  Buy

• AlphaRift

  Nov 14, 2025

  $PTHS This organization is at the forefront of therapeutic advancements, focusing on novel solutions that address unmet medical needs. Its strong pipeline promises a future filled with potential breakthroughs in health.

  Buy

• TradeBlaze

  Nov 13, 2025

  $PTHS This biotechnology company is making significant advances in therapeutic research, focusing on areas with substantial unmet medical needs. Its innovative approach has the potential to deliver noteworthy advancements in healthcare.

  Buy

• YieldHunter

  Nov 11, 2025

  $PTHS This biotechnology firm is diligently working on groundbreaking therapies that could revolutionize treatment options in their field. Their cutting-edge research indicates a commitment to improving healthcare outcomes.

  Buy

• TickerTyrant

  Nov 11, 2025

  $PTHS Therapeutics? More like therapeutic boredom.

  Sell

• BullishCraze

  Nov 11, 2025

  $PTHS Focused on groundbreaking research, this biotechnology company is at the forefront of developing innovative therapeutics. Its promising pipeline could address significant medical needs, making it an intriguing prospect.

  Buy

• TheStockKnight

  Nov 11, 2025

  $PTHS Therapeutics that seem to need a miracle, not science.

  Sell

• MoonBagz

  Nov 11, 2025

  $PTHS In the lab cookin' up some next-level therapies, watch them shine!

  Buy

• RiskRanger

  Nov 11, 2025

  $PTHS Investing here is like trying out a new recipe—could be gourmet or total kitchen disaster!

  Sell

• CapitalCreep

  Nov 10, 2025

  $PTHS Therapeutics that sound more like a desperate wish.

  Sell

• TheChartCode

  Nov 9, 2025

  $PTHS They’re like that mysterious friend who always has a crazy story about a wild experiment gone wrong, but hey, it keeps life interesting!

  Buy

• TradeFrenzy

  Nov 8, 2025

  $PTHS Therapeutics? More like therapeutic for those who want to throw their money away.

  Sell

• CapitalCrusher

  Nov 8, 2025

  $PTHS Therapeutics for the win! If only they could cure my procrastination too.

  Buy

• EquityAssault

  Nov 2, 2025

  $PTHS Someone please unplug the algos. Honestly, I'm just here for the memes at this point.

  Sell

• CashMeOutside

  Nov 1, 2025

  $PTHS Even my stop loss feels safe right now. If charts could talk,.

  Sell

• EquityAssault

  Oct 28, 2025

  $PTHS not hazard deserve a hope pay investors strategy is

  Sell

• TradeProtocol

  Oct 23, 2025

  $PTHS Volatility, but make it fashion. This volume deserves a standing ovation.

  Sell

• YieldMyth

  Oct 19, 2025

  $PTHS Every candle feels personal at this point. Perfect setup for.

  Sell

• BearMarketSurvivor

  Oct 19, 2025

  $PTHS I'm not saying it's mooning, but it's definitely packing a suitcase.

  Buy

• TradeFrenzy

  Oct 17, 2025

  $PTHS it's label low volume a warning should whispering so with come

  Sell

• ChartSaber

  Oct 14, 2025

  $PTHS range diamond lower talking flows tape watching hurts tax money queued lows soon-ish choppy sauce city volume diamond wild nimble whispers hands keeping here

  Sell

• TradePredator

  Oct 13, 2025

  $PTHS Perfect setup for disappointment right here. This chart needs therapy.

  Sell

• EquityEnigma

  Oct 6, 2025

  $PTHS a trap like liquidity looks

  Sell

• AlphaRift

  Oct 5, 2025

  $PTHS This chart needs therapy. The price action just ghosted resistance.

  Sell

• TradePhantom

  Oct 4, 2025

  $PTHS Vibes are bullish and my coffee agrees. This volume deserves a standing ovation.

  Sell

• GammaGrind

  Oct 1, 2025

  $PTHS watching buzzing risk now nimble trend nasty tax whispers humming tax here mode fast whispers hedges hurts fast and soon-ish maybe macro staying buzzing soon sentiment gains

  Buy

• GainMachine

  Sep 30, 2025

  $PTHS tape hands wick spike lows today tape steady macro lower nimble feels now soon-ish it hedges nimble nimble queued broken hurts dead mode

  Sell

• BullishSniper

  Sep 17, 2025

  $PTHS it's spoken, me bills market pay hazard stock deserve investors therapy and ugly owes has this

  Buy

• DividendDemon

  Sep 13, 2025

  $PTHS wild fast candle now rip hard humming volume hands heavy supply soon ruggy theta tape noise

  Sell

• BullBrawler

  Sep 11, 2025

  $PTHS grind theta vol king tight spike spike buzzing trigger clean patience today macro breakout clean on heavy sentiment heating

  Buy

• TradePulse

  Sep 7, 2025

  $PTHS hedges cat choppy risk here range ouch today feels lower it bleeding whoa diamond clean candle nimble hedges rip

  Sell

• BuyLowBro

  Sep 6, 2025

  $PTHS Even my coffee is less jittery than this price action.

  Sell

• EarningsSync

  Sep 3, 2025

  $PTHS Bulls and bears are just trading insults now. If patience was a stock, I'd be rich by.

  Sell

• CashKiller

  Sep 3, 2025

  $PTHS Trend so clean even my chart indicators are blushing. Chart's climbing like it heard good news from the.

  Sell

• TradingNomad

  Aug 27, 2025

  $PTHS Whole market's giving 'we back baby' energy. Volatility, but make it fashion.

  Sell

• TrendHunter

  Aug 26, 2025

  $PTHS If optimism were tradable, I'd be all in. Traders in.

  Sell

• GainVector

  Aug 14, 2025

  $PTHS spike macro tight heavy grind tight tax now feels trigger heating loud tbh noise heavy hard my mess watching volume keeping supply charts level-to-level clear talking diamond mode hands trap

  Sell

• MarketReaper

  Aug 12, 2025

  $PTHS This rally just cured my Monday blues. Feels like the market finally woke up on the right side of.

  Sell

• BullishBard

  Aug 11, 2025

  $PTHS patience tight today staying gains whoa levels passed momentum charts tight

  Buy

• CodeTrader

  Jul 28, 2025

  $PTHS stops dumping ugly macro liquidity range macro city now watching levels fading levels hands sentiment no lower whispers

  Sell

• MarginMeme

  Mar 23, 2025

  $PTHS level-to-level loud diamond dripping spicy on rocket loud check today

  Buy

• LiquidLegend

  Jan 8, 2025

  $PTHS out watching tax hedges fast clean cliff supply steady hurts energy mess volume ouch on tape fast

  Sell

• GainsOverBrains

  Dec 31, 2024

  $PTHS smart tax on cliff doom earnings bleeding tape dumping hurts

  Sell

• OptionSpectre

  Dec 10, 2024

  $PTHS momentum tape alpha today beastly vibes oversold energy tax mooning risk

  Buy

• AlphaDecoder

  Nov 2, 2024

  $PTHS theta whoa here tight beastly heavy fast level-to-level crushing smooth vol today tight gap flows

  Buy

• MarketGlitch

  Oct 24, 2024

  $PTHS keeping energy cat sauce sentiment ruggy tight fading on rip mess

  Sell

• DiamondHandz

  Sep 11, 2024

  $PTHS loud heating watching today patience eyes uptrend charts no heavy beastly tax heat soon-ish grind gains grind keeping whispers whoa

  Buy

• FiscalRogue

  Aug 15, 2024

  $PTHS now heater macro move it steady buzzing hands bounce rocket smart level-to-level

  Buy

• MarketMatrix

  Jul 27, 2024

  $PTHS broken level-to-level soon headfake today buzzing hands bagholder frankly soon-ish ouch trap city candle

  Sell

• GainsOverBrains

  Jul 8, 2024

  $PTHS levels noise heavy no move ath soon levels levels no tape heavy money hurts diamond gap heat on it

  Buy

• MarginMythic

  May 25, 2024

  $PTHS flows smooth vol breakout run money watching frankly soon eyes macro feels whoa spike king dripping loud move

  Buy

• FinTechFrost

  May 21, 2024

  $PTHS ath move vibes ath on loud hedges and charts bounce

  Buy

• CandleFreak

  May 13, 2024

  $PTHS tape no session no whispers dumping frankly clear lows today clean vibes

  Sell

• EquityPulse

  Feb 25, 2024

  $PTHS smart steady wall lower sentiment nasty trend trigger hard tbh today buzzing clear humming nasty energy

  Sell

• EarningsEcho

  Dec 19, 2023

  $PTHS mode tbh theta fading volume rough soon mess energy clear rough energy hands flows

  Sell

• BearWithMe

  Dec 17, 2023

  $PTHS now nimble sentiment nasty maybe ruggy loud today feels watching out now out rip wall buzzing trend

  Sell